Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teropavimab and Zinlirvimab with Lenacapavir in Virologically Suppressed HIV-1
NCT04811040Phase 1Completed
- Sponsor
- Gilead Sciences
- Start
- Apr 2021
- Primary completion
- Jun 2022
- Modality
- Anti-infectious Disease mAbs
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Teropavimab and zinlirvimab in human immunodeficiency virus type 1 infection (HIV-1) (4 cohorts), sponsored by Gilead Sciences. Primary endpoint: Percentage of Participants Experiencing Treatment-Emergent Serious Adverse Events at 26 weeks. Started Apr 2021; status: completed.
02
Drugs
Teropavimabzinlirvimab
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT04811040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04811040.